Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

NCCN Guidelines Insights: B-Cell Lymphomas, Version 5.2021.

NCCN Guidelines Insights: B-Cell Lymphomas, Version 5.2021. Journal of the National Comprehensive Cancer Network : JNCCN Zelenetz, A. D., Gordon, L. I., Chang, J. E., Christian, B., Abramson, J. S., Advani, R. H., Bartlett, N. L., Budde, L. E., Caimi, P. F., De Vos, S., Dholaria, B., Fakhri, B., Fayad, L. E., Glenn, M. J., Habermann, T. M., Hernandez-Ilizaliturri, F., Hsi, E., Hu, B., Kaminski, M. S., Kelsey, C. R., Khan, N., Krivacic, S., LaCasce, A. S., Lim, M., Narkhede, M., Rabinovitch, R., Ramakrishnan, P., Reid, E., Roberts, K. B., Saeed, H., Smith, S. D., Svoboda, J., Swinnen, L. J., Tuscano, J., Vose, J. M., Dwyer, M. A., Sundar, H. 2021; 19 (11): 1218-1230

Abstract

In the last decade, a better understanding of the molecular pathogenesis of B-cell non-Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as small molecule inhibitors of select kinases in the B-cell receptor pathway, antibody-drug conjugates, and small molecules that target a variety of proteins (eg, CD-19, EZH2, and XPO-1-mediated nuclear export). Anti-CD19 CAR T-cell therapy, first approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma, has also emerged as a novel treatment option for R/R follicular lymphoma and mantle cell lymphoma. These NCCN Guideline Insights highlight the new targeted therapy options included in the NCCN Guidelines for B-Cell Lymphomas for the treatment of R/R disease.

View details for DOI 10.6004/jnccn.2021.0054

View details for PubMedID 34781267